Lung cancer drug shows promise in stopping relapse after surgery
NCT ID NCT06352008
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether anlotinib hydrochloride capsules can help prevent lung cancer from coming back in patients who still had cancer cells after surgery and chemotherapy. About 64 adults with stage IIA-IIIA non-small cell lung cancer will take the drug daily. The main goal is to see how long patients stay cancer-free.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON-SMALL CELL LUNG CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Tianjin Medical University Cancer Institute & Hospital
RECRUITINGTianjin, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new immunotherapy combo outsmart advanced lung cancer?
- Double attack on mutant KRAS: can two targeted drugs outsmart resistant cancers?
- Seeing the fight: new imaging tracer may reveal how immune cells attack lung cancer
- Could a bronchial wash detect lung cancer mutations faster?
- Can a targeted pill outsmart a tough lung cancer mutation?
- Can a PET scan reveal hidden heart harm from lung cancer treatment?